Do multifocality, size of tumor or concomitant carcinoma in situ matter?
OBJECTIVES: In T1 bladder cancer (BC) multifocality, size of tumor (> or =3 cm) and concomitant carcinoma in situ (CIS) are used to stratify patients’ risk. We compared the long-term results in patients with initial T1G3 bc treated with transurethral resection of the bladder (TURB), bacille Calmette-Guérin (BCG) instillations and repeat resection with special regard to these clinical risk factors. The aim was to determine if they influence the outcome in the bladder sparing approach for initial T1G3 bc. METHODS: One hundred and thirty-two consecutive patients with initial T1G3 and no prior history of BC were identified. All patients completed six weekly adjuvant BCG instillations followed by control TURB. Follow-up consisted of cystoscopy with bladder wash cytology every 3 months for 2 years and every 6 months thereafter. RESULTS: Forty-two percent of patients had residual disease, 65% developed recurrence of any stage and 41% had progression to muscle-invasive disease. Cancer-specific
Related Questions
- What is the difference between invasive ductal carcinoma and ductal carcinoma in situ (DCIS) of the breast and how are they treated?
- How do we measure a residual tumor size in histopathology (the gold standard) after neoadjuvant chemotherapy?
- Do multifocality, size of tumor or concomitant carcinoma in situ matter?
